Literature DB >> 32268092

Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.

Nathan A Dahl1, Etienne Danis2, Ilango Balakrishnan2, Dong Wang2, Angela Pierce2, Faye M Walker2, Ahmed Gilani3, Natalie J Serkova4, Krishna Madhavan2, Susan Fosmire2, Adam L Green5, Nicholas K Foreman6, Sujatha Venkataraman2, Rajeev Vibhakar7.   

Abstract

Histone 3 gene mutations are the eponymous drivers in diffuse midline gliomas (DMGs), aggressive pediatric brain cancers for which no curative therapy currently exists. These recurrent oncohistones induce a global loss of repressive H3K27me3 residues and broad epigenetic dysregulation. In order to identify therapeutically targetable dependencies within this disease context, we performed an RNAi screen targeting epigenetic/chromatin-associated genes in patient-derived DMG cultures. This identified AFF4, the scaffold protein of the super elongation complex (SEC), as a molecular dependency in DMG. Interrogation of SEC function demonstrates a key role for maintaining clonogenic potential while promoting self-renewal of tumor stem cells. Small-molecule inhibition of SEC using clinically relevant CDK9 inhibitors restores regulatory RNA polymerase II pausing, promotes cellular differentiation, and leads to potent anti-tumor effect both in vitro and in patient-derived xenograft models. These studies present a rationale for further exploration of SEC inhibition as a promising therapeutic approach to this intractable disease.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AFF4; AZD4573; CDK9; DIPG; DMG; SEC; atuveciclib; diffuse intrinsic pontine glioma; diffuse midline glioma; super elongation complex

Mesh:

Substances:

Year:  2020        PMID: 32268092     DOI: 10.1016/j.celrep.2020.03.049

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  9 in total

1.  A Saccharomyces cerevisiae model and screen to define the functional consequences of oncogenic histone missense mutations.

Authors:  Laramie D Lemon; Sneha Kannan; Kim Wai Mo; Miranda Adams; Haley G Choi; Alexander O D Gulka; Elise S Withers; Hasset T Nurelegne; Valeria Gomez; Reina E Ambrocio; Rhea Tumminkatti; Richard S Lee; Morris Wan; Milo B Fasken; Jennifer M Spangle; Anita H Corbett
Journal:  G3 (Bethesda)       Date:  2022-07-06       Impact factor: 3.542

2.  Converging evidence for inhibition of transcriptional control in high-grade gliomas.

Authors:  Nathan A Dahl; Rajeev Vibhakar
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

3.  Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.

Authors:  Maria Wiese; Feda H Hamdan; Klaudia Kubiak; Christopher Diederichs; Gerrit H Gielen; Gunther Nussbaumer; Angel M Carcaboso; Esther Hulleman; Steven A Johnsen; Christof M Kramm
Journal:  Cell Death Dis       Date:  2020-08-21       Impact factor: 8.469

4.  Modeling by disruption and a selected-for partner for the nude locus.

Authors:  Jian Li; Yun-Kyoung Lee; Wenyu Fu; Anne M Whalen; Mario C Estable; Laurel A Raftery; Kristin White; Lorin Weiner; Janice L Brissette
Journal:  EMBO Rep       Date:  2020-12-28       Impact factor: 8.807

5.  AFF4 Predicts the Prognosis of Colorectal Cancer Patients and Suppresses Colorectal Cancer Metastasis via Promoting CDH1 Expression.

Authors:  Yi Fang; Hua Cao; Xiaoyong Gong; Yanqing Chen; Yugang Zhuang; Shuqin Zhou; Yuanzhuo Chen; Yimei Jiang; Xiaopin Ji; Hu Peng; Xiaoqian Jing
Journal:  Front Oncol       Date:  2022-02-09       Impact factor: 6.244

6.  Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.

Authors:  Hiroaki Katagi; Nozomu Takata; Yuki Aoi; Yongzhan Zhang; Emily J Rendleman; Gavin T Blyth; Frank D Eckerdt; Yusuke Tomita; Takahiro Sasaki; Amanda M Saratsis; Akihide Kondo; Stewart Goldman; Oren J Becher; Edwin Smith; Lihua Zou; Ali Shilatifard; Rintaro Hashizume
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 13.029

7.  Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.

Authors:  Ilango Balakrishnan; Etienne Danis; Angela Pierce; Krishna Madhavan; Dong Wang; Nathan Dahl; Bridget Sanford; Diane K Birks; Nate Davidson; Dennis S Metselaar; Michaël Hananja Meel; Rakeb Lemma; Andrew Donson; Trinka Vijmasi; Hiroaki Katagi; Ismail Sola; Susan Fosmire; Irina Alimova; Jenna Steiner; Ahmed Gilani; Esther Hulleman; Natalie J Serkova; Rintaro Hashizume; Cynthia Hawkins; Angel M Carcaboso; Nalin Gupta; Michelle Monje; Nada Jabado; Kenneth Jones; Nicholas Foreman; Adam Green; Rajeev Vibhakar; Sujatha Venkataraman
Journal:  Cell Rep       Date:  2020-10-20       Impact factor: 9.423

8.  Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma.

Authors:  Chen He; Ke Xu; Xiaoyan Zhu; Paige S Dunphy; Brian Gudenas; Wenwei Lin; Nathaniel Twarog; Laura D Hover; Chang-Hyuk Kwon; Lawryn H Kasper; Junyuan Zhang; Xiaoyu Li; James Dalton; Barbara Jonchere; Kimberly S Mercer; Duane G Currier; William Caufield; Yingzhe Wang; Jia Xie; Alberto Broniscer; Cynthia Wetmore; Santhosh A Upadhyaya; Ibrahim Qaddoumi; Paul Klimo; Frederick Boop; Amar Gajjar; Jinghui Zhang; Brent A Orr; Giles W Robinson; Michelle Monje; Burgess B Freeman Iii; Martine F Roussel; Paul A Northcott; Taosheng Chen; Zoran Rankovic; Gang Wu; Jason Chiang; Christopher L Tinkle; Anang A Shelat; Suzanne J Baker
Journal:  Nat Commun       Date:  2021-07-02       Impact factor: 14.919

Review 9.  Therapeutic Targets in Diffuse Midline Gliomas-An Emerging Landscape.

Authors:  Elisha Hayden; Holly Holliday; Rebecca Lehmann; Aaminah Khan; Maria Tsoli; Benjamin S Rayner; David S Ziegler
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.